<DOC>
	<DOCNO>NCT01112644</DOCNO>
	<brief_summary>The primary objective 12-week Titration-/Maintenance Period : To demonstrate superior efficacy OXN PR compare PLA improvement symptom severity RLS .</brief_summary>
	<brief_title>Oxycodone/Naloxone Prolonged Release ( OXN PR ) Compared Placebo Demonstrate Improvement Symptoms Restless Legs Syndrome ( RLS ) Subjects With Moderate Severe Idiopathic RLS With Daytime Symptoms</brief_title>
	<detailed_description>A randomised , double-blind , placebo-controlled , parallel-group , multicenter study demonstrate improvement symptom RLS subject moderate severe idiopathic RLS daytime symptom take oxycodone/naloxone prolong release ( OXN PR ) compare subject take placebo ( PLA ) .</detailed_description>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>Moderate severe idiopathic RLS daytime symptom Females pregnant lactating . Subjects evidence significant structural abnormality gastrointestinal tract . Subjects evidence impair liver/kidney function upon entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>